Christopher C Denton1, Yasmin A Rawlins2, Matthew J Oberley3,4, Deepa Bhojwani1,4, Etan Orgel1,4. 1. Division of Hematology, Oncology, & BMT, Children's Hospital Los Angeles, Los Angeles, California. 2. College of Physicians and Surgeons, Columbia University, New York, New York. 3. Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, California. 4. Keck School of Medicine, University of Southern California, Los Angeles, California.
Abstract
BACKGROUND: Hepatotoxicity and pancreatitis are common treatment-related toxicities (TRTs) during contemporary treatment regimens for acute lymphoblastic leukemia (ALL). Limited detailed data from Children's Oncology Group (COG) regimens has been previously reported to enable identification of patient and treatment risk factors for these toxicities and their impact on outcomes. PROCEDURE: We analyzed a retrospective pediatric ALL cohort treated at a single institution according to COG regimens from 2008 to 2015. The primary endpoint was cumulative incidence of study-defined "severe" hepatotoxicity (Common Terminology Criteria for Adverse Events [CTCAE] Grade ≥ 4 transaminitis or Grade ≥ 3 hyperbilirubinemia) and clinically significant pancreatitis (any grade). Pancreatitis was additionally classified using the Ponte di Legno (PdL) toxicity criteria. Secondary endpoints were chemotherapy interruptions, early disease response (end of induction [EOI] minimal residual disease [MRD]), and event-free survival (EFS). RESULTS: We identified 262 patients, of whom 71 (27%) and 28 (11%) developed hepatotoxicity and pancreatitis, respectively. Three cases of pancreatitis did not fulfill PdL criteria despite otherwise consistent presentations. Both TRTs occurred throughout therapy, but approximately 25% of hepatotoxicity (18/71) and pancreatitis (8/28) occurred during induction alone. Both obesity and age (≥10 years) were identified as predictors of hepatotoxicity (subdistribution hazard ratio [SHR] obesity = 1.75, 95% confidence interval [95% CI] 1.04-2.96; SHR age ≥10 = 1.9, 95% CI 1.19-3.10) and pancreatitis (SHR obesity = 2.18, 95% CI 1.01-4.67; SHR age ≥ 10 = 2.76, 95% CI 1.19-6.39, P = 0.018). Dose interruptions were common but neither toxicity influenced EOI MRD nor EFS. CONCLUSIONS: Obese and/or older children are particularly at risk for hepatotoxicity and pancreatitis, and may benefit from toxicity surveillance and chemoprotective strategies to prevent or mitigate associated morbidity.
BACKGROUND:Hepatotoxicity and pancreatitis are common treatment-related toxicities (TRTs) during contemporary treatment regimens for acute lymphoblastic leukemia (ALL). Limited detailed data from Children's Oncology Group (COG) regimens has been previously reported to enable identification of patient and treatment risk factors for these toxicities and their impact on outcomes. PROCEDURE: We analyzed a retrospective pediatric ALL cohort treated at a single institution according to COG regimens from 2008 to 2015. The primary endpoint was cumulative incidence of study-defined "severe" hepatotoxicity (Common Terminology Criteria for Adverse Events [CTCAE] Grade ≥ 4 transaminitis or Grade ≥ 3 hyperbilirubinemia) and clinically significant pancreatitis (any grade). Pancreatitis was additionally classified using the Ponte di Legno (PdL) toxicity criteria. Secondary endpoints were chemotherapy interruptions, early disease response (end of induction [EOI] minimal residual disease [MRD]), and event-free survival (EFS). RESULTS: We identified 262 patients, of whom 71 (27%) and 28 (11%) developed hepatotoxicity and pancreatitis, respectively. Three cases of pancreatitis did not fulfill PdL criteria despite otherwise consistent presentations. Both TRTs occurred throughout therapy, but approximately 25% of hepatotoxicity (18/71) and pancreatitis (8/28) occurred during induction alone. Both obesity and age (≥10 years) were identified as predictors of hepatotoxicity (subdistribution hazard ratio [SHR] obesity = 1.75, 95% confidence interval [95% CI] 1.04-2.96; SHR age ≥10 = 1.9, 95% CI 1.19-3.10) and pancreatitis (SHR obesity = 2.18, 95% CI 1.01-4.67; SHR age ≥ 10 = 2.76, 95% CI 1.19-6.39, P = 0.018). Dose interruptions were common but neither toxicity influenced EOI MRD nor EFS. CONCLUSIONS:Obese and/or older children are particularly at risk for hepatotoxicity and pancreatitis, and may benefit from toxicity surveillance and chemoprotective strategies to prevent or mitigate associated morbidity.
Authors: Stephen P Hunger; Xiaomin Lu; Meenakshi Devidas; Bruce M Camitta; Paul S Gaynon; Naomi J Winick; Gregory H Reaman; William L Carroll Journal: J Clin Oncol Date: 2012-03-12 Impact factor: 44.544
Authors: D M Reddi; A S Barbas; A W Castleberry; A S Rege; D S Vikraman; T V Brennan; K V Ravindra; B H Collins; D L Sudan; A S Lagoo; A E Martin Journal: Pediatr Transplant Date: 2014-01-20
Authors: Elena J Ladas; David J Kroll; Nicholas H Oberlies; Bin Cheng; Deborah H Ndao; Susan R Rheingold; Kara M Kelly Journal: Cancer Date: 2010-01-15 Impact factor: 6.860
Authors: Michael J Borowitz; Meenakshi Devidas; Stephen P Hunger; W Paul Bowman; Andrew J Carroll; William L Carroll; Stephen Linda; Paul L Martin; D Jeanette Pullen; David Viswanatha; Cheryl L Willman; Naomi Winick; Bruce M Camitta Journal: Blood Date: 2008-04-03 Impact factor: 22.113
Authors: Eric C Larsen; Meenakshi Devidas; Si Chen; Wanda L Salzer; Elizabeth A Raetz; Mignon L Loh; Leonard A Mattano; Catherine Cole; Alisa Eicher; Maureen Haugan; Mark Sorenson; Nyla A Heerema; Andrew A Carroll; Julie M Gastier-Foster; Michael J Borowitz; Brent L Wood; Cheryl L Willman; Naomi J Winick; Stephen P Hunger; William L Carroll Journal: J Clin Oncol Date: 2016-04-25 Impact factor: 44.544
Authors: Ajay Vora; Chris D Mitchell; Lynne Lennard; T O B Eden; Sally E Kinsey; John Lilleyman; Sue M Richards Journal: Lancet Date: 2006-10-14 Impact factor: 79.321
Authors: Saman K Hashmi; Shoba A Navai; Tiffany M Chambers; Michael E Scheurer; M John Hicks; Rachel E Rau; Maria M Gramatges Journal: Pediatr Blood Cancer Date: 2019-11-17 Impact factor: 3.167
Authors: Anjali S Advani; Eric Larsen; Kristina Laumann; Selina M Luger; Michaela Liedtke; Meenakshi Devidas; Zhiguo Chen; Jun Yin; Matthew C Foster; David Claxton; Kristin Coffan; Martin S Tallman; Frederick R Appelbaum; Harry Erba; Richard M Stone; Stephen P Hunger; Jennifer L McNeer; Mignon L Loh; Elizabeth Raetz; Naomi Winick; William Carroll; Richard A Larson; Wendy Stock Journal: Blood Adv Date: 2021-01-26
Authors: Zachary E West; Sharon M Castellino; Caitlin Monroe; Amanda S Thomas; Courtney McCracken; Tamara P Miller Journal: Leuk Lymphoma Date: 2020-12-01
Authors: Jessica L Sea; Etan Orgel; Ting Chen; Rebecca L Paszkiewicz; Abigail S Krall; Matthew J Oberley; Linsey Stiles; Steven D Mittelman Journal: Leuk Lymphoma Date: 2019-09-16
Authors: Jeremy M Schraw; J P Woodhouse; Melanie B Bernhardt; Olga A Taylor; Terzah M Horton; Michael E Scheurer; M Fatih Okcu; Karen R Rabin; Philip J Lupo; Austin L Brown Journal: Sci Rep Date: 2021-10-04 Impact factor: 4.379
Authors: Rachael Schulte; Ashley Hinson; Van Huynh; Erin H Breese; Joanna Pierro; Seth Rotz; Benjamin A Mixon; Jennifer L McNeer; Michael J Burke; Etan Orgel Journal: Cancer Med Date: 2021-09-16 Impact factor: 4.452